O-(2-Fluoro-ethyl)-hydroxylamine | 91592-21-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: O-(2-Fluoro-ethyl)-hydroxylamine
• 英文别名: O-(2-fluoroethyl)hydroxylamine
• CAS: 91592-21-1
• 化学式: C₂H₆FNO
• 分子量: 79.0741
• InChiKey: RODRJIHHHOKCLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  5
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-N-(2,2-(dimethoxy)ethyl)-1-naphthamide 、 O-(2-Fluoro-ethyl)-hydroxylamine 在 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 16.0h， 生成 (E/Z)-4-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-N-(2((2-fluoroethoxy)imino)ethyl)-1-naphthamide
  参考文献：
  名称：

  ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS

  摘要：

  这项发明涉及公式（1）的萘异噁唑啉肟衍生物的几何异构体、立体异构体、药用或兽医学上可接受的盐、组合物以及它们作为动物寄生虫药的用途。变量R1a、R1b、R1c、R2、R3如本文所述。

  公开号：

  US20120077765A1

文献信息

• Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
  申请人：——

  公开号：US20020099208A1

  公开（公告）日：2002-07-25

  The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides heterocyclic substituted 2-methylbenzimidazole derivatives for the treatment of respiratory syncytial virus infection.

  本发明涉及抗病毒化合物，其制备方法及其组合物，以及在治疗病毒感染中的应用。更具体地，本发明提供了用于治疗呼吸道合胞病毒感染的杂环取代的2-甲基苯并咪唑衍生物。
• Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships
  作者：Katsuki Yokoo、Kenji Yamawaki、Yutaka Yoshida、Shuji Yonezawa、Yoshinori Yamano、Masakatsu Tsuji、Toshihiko Hori、Rio Nakamura、Koji Ishikura

  DOI：10.1016/j.ejmech.2016.09.015

  日期：2016.11

  A series of novel 7 beta-[2-(2-aminothiazole-4-yl)-2-(Z)-(alkoxyimino)acetamidol-cephalosporins having pyridinium-linked acyl cyanamide at the C-3 position were prepared and their antibacterial activities and pharmacokinetics profiles were evaluated. Most of the compounds exhibited potent antibacterial activities against penicillin-resistant Streptococcus pneumoniae (PRSP) and beta-lactamase non-producing penicillin-resistant Haemophilus influenzae (BLNAR). Introduction of a propenyl group between the cephalospoin core and the side chains at the C-3 position improved the pharmacokinetics profile. Among these compounds, 7 beta-[2-(2-aminothiazole-4-y1)-2-(Z)- (alkoxyimino)acetamido1-3-(pyridin-1-ium-1-yl) prop-1-en-1-yl)cephalosporins (32j) showed well-balanced antibacterial activity against S. pneumoniae and H. influenzae which included resistant strains and also other Gram-positive or Gram-negative pathogens. Furthermore, 32j showed a long half-life comparable to that of Ceftriaxone in mice and monkeys. (C) 2016 Elsevier Masson SAS. All rights reserved.
• ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS
  申请人：Curtis Michael

  公开号：US20120077765A1

  公开（公告）日：2012-03-29

  This invention recites naphthyl isoxazoline oxime derivatives of Formula (1) geometric isomers, stereoisomers thereof, pharmaceutically or veterinarily acceptable salts thereof, compositions thereof, and their use as a parasiticide in animals. The variables, R 1a , R 1b , R 1c , R 2 , R 3 , and are as described herein.

  这项发明涉及公式（1）的萘异噁唑啉肟衍生物的几何异构体、立体异构体、药用或兽医学上可接受的盐、组合物以及它们作为动物寄生虫药的用途。变量R1a、R1b、R1c、R2、R3如本文所述。